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Abstract
Weight-loss interventions generally improve lipid profiles and reduce cardiovascular disease risk, but effects are variable and
may depend on genetic factors. We performed a genetic association analysis of data from 2,993 participants in the Diabetes
Prevention Program to test the hypotheses that a genetic risk score (GRS) based on deleterious alleles at 32 lipid-associated
single-nucleotide polymorphisms modifies the effects of lifestyle and/or metformin interventions on lipid levels and nuclear
magnetic resonance (NMR) lipoprotein subfraction size and number. Twenty-three loci previously associated with fasting
LDL-C, HDL-C, or triglycerides replicated (P=0.04–1610
217). Except for total HDL particles (r=20.03, P=0.26), all
components of the lipid profile correlated with the GRS (partial |r|=0.07–0.17, P=5 610
25–1610
219). The GRS was
associated with higher baseline-adjusted 1-year LDL cholesterol levels (b=+0.87, SEE60.22 mg/dl/allele, P=8 610
25,
Pinteraction=0.02) in the lifestyle intervention group, but not in the placebo (b=+0.20, SEE60.22 mg/dl/allele, P=0.35) or
metformin (b=20.03, SEE60.22 mg/dl/allele, P=0.90; Pinteraction=0.64) groups. Similarly, a higher GRS predicted a greater
number of baseline-adjusted small LDL particles at 1 year in the lifestyle intervention arm (b=+0.30, SEE60.012 ln nmol/L/
allele, P=0.01, Pinteraction=0.01) but not in the placebo (b=20.002, SEE60.008 ln nmol/L/allele, P=0.74) or metformin
(b=+0.013, SEE60.008 nmol/L/allele, P=0.12; Pinteraction=0.24) groups. Our findings suggest that a high genetic burden
confers an adverse lipid profile and predicts attenuated response in LDL-C levels and small LDL particle number to dietary
and physical activity interventions aimed at weight loss.
Citation: Pollin TI, Isakova T, Jablonski KA, de Bakker PIW, Taylor A, et al. (2012) Genetic Modulation of Lipid Profiles following Lifestyle Modification or Metformin
Treatment: The Diabetes Prevention Program. PLoS Genet 8(8): e1002895. doi:10.1371/journal.pgen.1002895
Editor: David B. Allison, University of Alabama at Birmingham, United States of America
Received March 26, 2012; Accepted June 26, 2012; Published August 30, 2012
Copyright:  2012 Pollin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health provided funding to the clinical
centers and the Coordinating Center for the design and conduct of the study, and collection, management, analysis, and interpretation of the data. The
Southwestern American Indian Centers were supported directly by the NIDDK and the Indian Health Service. The General Clinical Research Center Program,
National Center for Research Resources, supported data collection at many of the clinical centers. Funding for data collection and participant support was also
provided by the Office of Research on Minority Health, the National Institute of Child Health and Human Development, the National Institute on Aging, the
Centers for Disease Control and Prevention, the Office of Research on Women’s Health, and the American Diabetes Association. Bristol-Myers Squibb and Parke-
Davis provided medication. This research was also supported, in part, by the intramural research program of the NIDDK. LifeScan, Health O Meter, Hoechst Marion
Roussel, Merck-Medco Managed Care, Merck, Nike Sports Marketing, Slim Fast Foods, and Quaker Oats donated materials, equipment, or medicines for
concomitant conditions. McKesson BioServices, Matthews Media Group, and the Henry M. Jackson Foundation provided support services under subcontract with
the Coordinating Center. The opinions expressed are those of the investigators and do not necessarily reflect the views of the Indian Health Service or other
funding agencies. A complete list of centers, investigators, and staff is shown in the Acknowledgments. Genetics research in the DPP and the work reported in this
manuscript was supported in part by R01 DK072041 to DA, JCF, KAJ, TIP, and ARS (PWF was an unpaid co-investigator) and by a Doris Duke Charitable Foundation
Distinguished Scientist Clinical Award to DA. TI was supported by NIH grant K23DK087858. JCF is supported by a Physician Scientist Development Award by the
PLOS Genetics | www.plosgenetics.org 1 August 2012 | Volume 8 | Issue 8 | e1002895Massachusetts General Hospital and a Clinical Scientist Development Award from the Doris Duke Charitable Foundation. PWF was supported by the Swedish
Research Council, Swedish Heart-Lung Foundation, Pa ˚hlssons Foundation, and Novo Nordisk Foundation. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: TIP has been a consultant for Isis Pharmaceuticals. TI has received a research grant from NIDDK and honoraria from Shire and Genzyme
and has been a consultant for Shire. KAJ (the DPP Genetics Program) has a research grant from NIH. DA has received a research grant from Pfizer and honoraria
from academic non-profit (e.g. talks) and has been a consultant for Eisai, MPM Capital, and NanoString. ARS has a NIH research grant. RBG has a research grant
from NIH for this study; speaker honoraria from Merck; other research support from Bristol Myers Squibb, GSK, and Roche; and small consultant activities. JCF has
received consulting honoraria from Daiichi-Sankyo and AstraZeneca. PWF has received speaking honoraria from Novo Nordisk and other academic/non-profit
organisations.
* E-mail: paul.franks@med.lu.se (PWF); dppmail@biostat.bsc.gwu.edu (DPPRG)
. These authors contributed equally to this work.
" Membership of the Diabetes Prevention Program Research Group is provided in the Acknowledgments.
Introduction
Dyslipidemia is a strong risk factor for atherosclerotic heart
disease [1–3], has a well-defined genetic basis [4], and is
modifiable through therapeutic lifestyle changes and weight-loss
interventions [5,6]. Individuals at risk for diabetes are also at high
risk of cardiovascular disease [7], and individualized lifestyle
intervention programs, like the one incorporated into the Diabetes
Prevention Program (DPP), have a salutary effect on dyslipidemia
and cardiovascular disease risk in this population. However, the
cost of widespread implementation of such interventions has been
highlighted as a major limitation [8] and not all benefit equally
from such interventions. Identifying persons most likely to benefit
from intensive lifestyle modification could provide justification for
targeting this subpopulation first, making the clinical translation of
findings from studies such as the DPP more feasible.
Selection of persons whose dyslipidemia is likely to respond well
to lifestyle interventions or pharmacotherapy could help target
resources and optimize prevention strategies. To do so requires
knowledge of the underlying risk factors for the trait and
knowledge of how personal characteristics interact with exercise,
diet, and weight loss. Although the heritability of polygenic
dyslipidemia [9–11] and its sequelae [12] have been elucidated,
little is known of how lifestyle interventions modify the effects of
these loci, singly or in combination, on lipid profiles. Thus,
learning how a person’s genetic background modulates his or her
response to therapeutic lifestyle changes and weight-loss interven-
tions might help optimize the targeting of interventions designed to
mitigate cardiovascular and metabolic disease risk.
The purpose of this study was to examine whether loci reliably
associated with polygenic dyslipidemia modified the response to
cardio-protective interventions in the DPP, a randomized clinical
trial of intensive lifestyle modification, metformin treatment, or
placebo with standard care. We hypothesized i) that the baseline
lipid profiles of DPP participants would be associated with gene
variants known to associate with polygenic dyslipidemia and ii)
that improvement in lipidemia following treatment would depend
on these same genetic variants. We also used NMR spectroscopy
to characterize the associations of these previously reported loci
with lipoprotein subfractions.
Results
Table 1 shows participant characteristics stratified by DPP
treatment arm. The effects of the DPP interventions on 1 yr
changes in weight [14], insulin secretion [13], beta-cell function
[13], and lipid traits [29] are reported in detail elsewhere.
Individual SNP Replication
Thirty-two SNPs previously associated with triglycerides (TG),
low-density lipoprotein-cholesterol (LDL-C) and/or high-density
lipoprotein-cholesterol (HDL-C) levels were considered [10].
Thirty-one of these were successfully genotyped in the DPP, and
two SNPs in CETP, serving as HapMap proxies (r
2$0.90) for
rs173539, including rs247616, were subsequently successfully
genotyped, with rs247616 retained as the replacement for
rs173539. Twenty-three of these 32 non-redundant SNPs repli-
cated with their respective traits in a directionally consistent
manner (P#0.05), including 8/11 for TG, 9/14 for HDL-C and
8/11 for LDL-C. Two of the SNPs, rs12678919 and rs964184,
replicated for both HDL-C and TG (Table S1).
Association of Individual SNPs with All Four Lipid Traits
and Ten Lipoprotein Traits
Additionally, we evaluated the associations of the 32 lipid loci
with baseline lipids and nuclear magnetic resonance (NMR)-
derived lipoprotein traits (Large HDL particles, Small HDL
particles, Total HDL particles, HDL size, LDL size, Total LDL
particles, Small LDL particles, Total VLDL particles, Large
VLDL particles, VLDL size). Of all analyses of baseline traits,
roughly one third of the tests were nominally significant
associations, and 35 associations were significant after correcting
for all 448 hypothesis tests; these involved 12 SNPs and 13 traits
(Table S2). Interestingly, SNP rs10401969 did not replicate for
LDL-C (C vs. T: b6SEM=20.161.6 mg/dl, additive P=0.94),
but was associated with decreased large VLDL (mean 5.43, 4.26,
4.07 nmol/L for TT, TC, CC genotypes respectively, additive
P=4 610
25) and smaller VLDL size (53.18, 50.94, 49.55 nm,
P=2 610
26). SNP rs7679 did not quite reach nominal significance
for decreased HDL-C (C vs. T: b 6SEM=20.01660.009 ln mg/
dl, additive P=0.07), but was very strongly associated with
increased small HDL particle number (17.93, 20.14 and
21.89 mmol/L for TT, CT and CC genotypes respectively;
additive P=4 610
218) and consequently total HDL particle
number (34.07, 35.10 and 36.78 mmol/L, P=2 610
25).
Association of Genetic Risk Score (GRS) with Baseline
Lipid and Lipoprotein Traits
A lipid GRS was calculated for each individual by first replacing
missing genotypes with ethnicity-specific imputed means and then
adding up the number of risk alleles possessed for each of the 32
independent SNPs. Of the 32 SNPs evaluated, 11 were originally
associated in the meta-analysis with LDL cholesterol, 10 with
HDL cholesterol only, seven with triglycerides only, and four with
both HDL cholesterol and triglycerides. A risk allele was defined as
one associated with increased TG or LDL-C or decreased HDL in
the original meta-analysis [10]. After adjustment for age, sex,
ethnicity, and BMI, the GRS was significantly associated with all
baseline traits evaluated except total HDL particles (P=0.26,
Table 2). The following are P-values for the effects of the GRS, as
a quantitative covariate, and geometric means for the upper and
Genetics, Weight Loss Interventions, and Lipidemia
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GRS was associated with elevated baseline levels of: total
cholesterol (P=4 610
211, 206 vs. 195 mg/dl), LDL-C
(P=9 610
28, 129 vs. 121 mg/dl; arithmetic means), TG
(P=4 610
219, 160 vs. 127 mg/dl), total VLDL particles
(P=6 610
214, 67 vs. 53 nmol/L), large VLDL particles
(P=1 610
214, 6.57 vs. 4.21 nmol/L), total LDL particles
(P=2 610
210, 1412 vs. 1262 nmol/L), small LDL particles
(P=2 610
211, 743 vs. 543 nmol/L), small HDL particles
(P=0.0005, 19.17 vs. 18.10 mmol/L), and VLDL particle size
(P=1 610
25, 53.86 vs. 51.84 nm). A higher GRS was also
associated with lower baseline levels of: HDL-C (P=1 610
215,
43 vs. 47 mg/dl), LDL particle size (P=1 610
219, 0.256 vs.
0.269 nm), large HDL particles (P=2 610
28, 2.98 vs. 3.68 mmol/
L), and HDL particle size (P=0.0003, 8.82 vs. 8.90 nm). All of
these results are consistent with a greater number of risk alleles
increasing the atherogenicity of the lipoprotein profile.
GRS6Intervention Interactions of Baseline-Adjusted One-
Year Traits
Two traits showed evidence of GRS6lifestyle interaction: LDL-
C( P=0.02) and small LDL particles (P=0.01, Table 3; Figure 1;
Figure S1a–S1f). For these two traits, there was a residual
detrimental impact of GRS in the lifestyle (i.e., the GRS was
associated with higher levels at one year even after adjusting for
baseline levels) but not the metformin or placebo group, suggesting
that the lifestyle intervention was less effective at lipid-lowering in
those with a higher genetic burden. A unit (allele) GRS increase
was associated with higher residual LDL-C levels in the lifestyle
group (b+0.087, SEE60.022 mg/dl, P=8 610
25) but not in the
metformin (b20.03, SEE60.22 mg/dl, P=0.90) or placebo
(b+0.20, SEE60.22 mg/dl, P=0.35) groups (Figure 1). Similarly,
the GRS was associated with higher residual ln-small LDL
particles in the lifestyle group (b+0.030, SEE60.0.012 ln nmol/L,
P=0.01), but not in the metformin (b20.013, SEE60.008 ln nm/
Table 1. Baseline Characteristics of the Study Population by Treatment Group [Quantitative Traits Are Shown as Median
(Interquartile Range)].
Trait Placebo Metformin Lifestyle
n 947 939 962
Age 49 (43–57) 50 (44–57) 49 (42–58)
Sex [M:F (% male)] 290:657 (31% male) 321:618 (34% male) 308:654 (32% male)
White/AA/Hisp/Asian/AI: n (%) 515(54)/207(22)/157(17)/38(4)/30(3) 534(57)/194(21)/155(17)/33(4)/23(3) 517(54)/191(20)/173(18)/53(6)/28(3)
BMI (kg/m
2) 33.4 (29.2–38.3) 33.0 (29.1–37.7) 32.8 (29.0–37.3)
Waist Circumference (cm) 104.4 (95–114.7) 104.3 (94.7–114.0) 103.8 (95.0–113.6)
Total Cholesterol (mg/dl) 201 (178–227) 202 (177–225) 202 (179–227)
LDL-C (mg/dl) 123 (102–147) 123 (103–145) 124 (102–145)
HDL-C (mg/dl) 43 (37–50) 44 (38–52) 44 (37–53)
Triglycerides (mg/dl) 146 (102.5–205.5) 135 (97–195) 136 (94–200)
Large HDL particles (umol/L) 3.3 (2.1–5.5) 3.4 (2.2–5.3) 3.3 (2.2–5.4)
Small HDL particles (umol/L) 19 (16.1–22.2) 19.2 (16.3–22.6) 18.9 (15.8–21.8)
Total HDL particles (umol/L) 34.1 (30.4–38.5) 34.7 (31.2–38.9) 33.95 (30.2–38.1)
HDL size (nm) 8.8 (8.6–9.1) 8.8 (8.6–9.1) 8.8 (8.6–9.1)
LDL size (nm) 0.263 (0.237–0.289) 0.263 (0.237–0.289) 0.263 (0.237–0.289)
Total LDL particles (nmol/L) 1369 (1140–1629) 1367 (1108–1607) 1332 (1123–1591)
Small LDL particles (nmol/L) 788 (517–1059) 779 (525–1041) 764 (520–1040)
Total VLDL particles (nmol/L) 63.3 (43.9–88.1) 62.4 (42.6–86.2) 63.2 (42.1–88.5)
Large VLDL particles (nmol/L) 5.4 (2.8–10.8) 6.1 (2.8–11) 5.9 (2.7–10.8)
VLDL size (nm) 52.2 (47.0–58.9) 53.0 (46.9–59.4) 52.8 (47.0–59.0)
doi:10.1371/journal.pgen.1002895.t001
Author Summary
The study included 2,993 participants from the Diabetes
Prevention Program, a randomized clinical trial of intensive
lifestyle intervention, metformin treatment, and placebo
control. We examined associations between 32 gene
variants that have been reproducibly associated with
dyslipidemia and concentrations of lipids and NMR
lipoprotein particle sizes and numbers. We also examined
whether genetic background influences a person’s re-
sponse to cardioprotective interventions on lipid levels.
Our analysis, which focused on determining whether
common genetic variants impact the effects of cardiopro-
tective interventions on lipid and lipoprotein particle size,
shows that in persons with a high genetic risk score the
benefit of intensive lifestyle intervention on LDL and small
LDL particle levels is substantially diminished; this infor-
mation may be informative for the targeted prevention of
dyslipidemia, as it suggests that genetics might help
identify persons in whom lifestyle intervention is likely to
be an effective treatment for elevated lipids and lipopro-
teins. The NMR subfraction analyses provide novel insight
into the biology of dyslipidemia by illustrating how
numerous genetic variants that have previously been
associated with lipid levels also modulate NMR lipoprotein
particle sizes and number. This information may be
informative for the targeted prevention of cardiovascular
disease.
Genetics, Weight Loss Interventions, and Lipidemia
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(Figure 1). There were no metformin6GRS interactions significant
at the P=0.05 level. In addition to the three traits discussed,
several traits showed residual detrimental effects of the GRS in one
or more strata (total cholesterol, TG, LDL size, total VLDL
particles, large HDL particles, and HDL size) without any
statistical evidence of treatment6GRS interaction (Table 3).
Discussion
In the present study, the majority of previously associated SNPs
replicated for baseline lipid traits, and there was a statistically
significant relationship between the GRS and the vast majority of
standard lipid traits and NMR lipoprotein subfractions. Impor-
tantly, in several cases the evidence for association with NMR
subfractions was much stronger than for the original standard lipid
trait, which may be owing to the relative proximity of the
subfractions to the genetic loci. For example, SNP rs7679,
originally associated with total HDL–C levels in previous GWASs,
in the DPP was not significantly associated with HDL-C (P=0.07)
but was strongly associated with small HDL particle levels
(P=4 610
218). This SNP is near PLTP, encoding phospholipid
transfer protein, a molecule directly influencing HDL particle size
[14]. Such findings extend our understanding of lipid biology and
suggest that, compared to standard lipid levels, measurements of
lipoprotein subfractions may provide a more effective way of
capturing genetically influenced risk. This is particularly impor-
tant, as recent studies have shown that HDL-C is a heterogeneous
trait, which in the context of clinical use may benefit from sub-
stratification by genotype [15].
We also observed that within the lifestyle group but not the
placebo or metformin groups, the GRS was associated with higher
LDL-C and small LDL particle levels after one year of
intervention. These findings suggest that the genetic burden on
these traits cannot be completely overcome by lifestyle modifica-
tion. However, even those with the greatest genetic burden benefit
to a limited extent from lifestyle intervention in terms of LDL-C
reduction (Figure 1A), although the effect on LDL particle size
reduction is almost completely ablated (Figure 1B). Even a true
residual effect of lifestyle on LDL-C in people with the highest
GRS does not negate the clinical relevance of our findings in terms
of potential to facilitate tailored treatment decisions. Seeing less of
an effect of lifestyle in a particular patient subgroup indicates that
these persons may benefit from more frequent surveillance, more
intense lifestyle interventions, or aggressive pharmaceutical inter-
ventions to supplement lifestyle interventions. Conversely, know-
ing that lifestyle intervention is likely to be adequate in persons
with the lowest genetic burden may maximize the patient’s diet
adherence and potentially reduce the costs and side effects
associated with prescribing lipid-lowering medications unneces-
sarily. The availability of information on genetic background may
also facilitate patient-provider dialogue, owing to improved
diagnostic accuracy. This is similar to the strategy used to control
cholesterol levels in patients with a monogenic disorder such as
familial hypercholesterolemia due to a severe loss of function
mutation in LDLR, where lifestyle intervention combined with
pharmacotherapy is needed to bring LDL-C levels within an
acceptable range (Third Report of the NCEP-ATP III on the
Detection, Evaluation, and Treatment of High Blood Cholesterol
in Adults).
It is also important to bear in mind that the interaction effects
may be underestimated in our paper. This is because the majority
of SNPs included in the GRS are likely to be imperfect proxies for
unobserved functional variants, resulting in some degree of
genotype misclassification. Moreover, all 32 SNPs were included
within the GRS, even though not all SNPs convey statistically
significant effects in the DPP and do not individually modify the
effects of the interventions. A parsimonious GRS including only
those SNPs that are statistically significant in the DPP would likely
be overfitted to our data, resulting in biased conclusions about the
strength and magnitude of gene6treatment interactions.
Dyslipidemia is a long-established risk factor for CVD [1–3].
Thus, the primary and secondary prevention of atherosclerotic
CVD often involves intervening on lipid levels [16]. Lifestyle
interventions [17] and metformin treatment [18] that result in
weight loss have the potential to improve lipid profiles; neverthe-
less, as long recognized [19], changes in lipid profiles following
interventions vary greatly from one person to the next. Some of
the variability in response to interventions may be because
genotypes modulate the effects of preventive interventions on lipid
homeostasis and CVD risk [20].
Of the many known dyslipidemia-predisposing loci discovered
so far [10], only a handful have been the focus of studies testing
hypotheses of gene6treatment interactions [21–28], and most of
these studies are small (N,150), non-randomized trials of dietary
intervention. Although some of these studies have focused on
genomic regions that are confirmed to harbor dyslipidemia-
predisposing loci, such as APOB, CETP, LIPC and LPL [21,22,24–
28], no exhaustive studies testing whether GWAS-discovered loci
[10,29,30] modify response to treatments have been previously
reported.
The GRS used in this study attenuated the impact of the DPP
lifestyle intervention on LDL levels and small LDL particle
number. This suggests that a genetic predisposition to high LDL
levels and more small LDL particles is difficult to overcome
through lifestyle intervention alone. These data also unmask the
effects of an underlying genetic defect of LDL levels and small
LDL particles found in individuals with a high genetic burden,
which becomes visible when adiposity and blood TG content are
reduced through lifestyle intervention. This information may
justify the combination of lifestyle and lipid lowering drug
treatment from the outset in these individuals, rather than the
usual approach of stepping from lifestyle to drug therapy when the
former fails.
The DPP lifestyle intervention prioritized weight loss, daily fat
gram intake and physical activity goals over intake of saturated fat,
cholesterol, viscous fiber and plant stanols/sterols; this may have
influenced the nature of the changes in the lipid profile. When
compared to the metformin and placebo groups, the lifestyle
intervention group reported improved physical activity levels and
reductions in calorie intake, resulting in significantly greater
weight losses [31], each of which has major influences on TG
levels. The lifestyle intervention group reported significantly
greater reductions in percent calories from total fat and saturated
fat than the metformin and placebo groups [31]. However, they
did not, on average, achieve the National Cholesterol Education
Program target for saturated fat intake and did not focus on the
other therapeutic lifestyle changes, such as the additional dietary
changes mentioned above, that often have the largest effects on
LDL concentrations. The ethnic diversity of the DPP cohort
facilitates the generalizability of results, but may also lead to
confounding by population stratification in genetic analyses.
However, Sensitivity analyses in the European White sub-cohort
of the DPP yielded comparable effect estimates to the results
obtained in the entire DPP genetics cohort (results for baseline
traits shown in Table S3), supporting the conclusion that
confounding by population stratification is unlikely to explain
our findings.
Genetics, Weight Loss Interventions, and Lipidemia
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the GRS and other biochemical components of the lipid profile in
the present study. It is important to bear in mind, however, that
despite being the largest clinical trial of its kind, the DPP is only
moderately powered to detect gene6treatment interactions [32]; it
is likely, therefore, that gene6treatment interactions that are small
in magnitude will have been overlooked here. Moreover, during
the course of writing this paper, many smaller impact lipid loci
have been discovered [9,11]. Thus, it is possible that with a larger
sample size and the inclusion of some or all of these additional loci,
we may have discovered interaction effects on other lipid traits.
In summary, we have shown that common genetic loci that
influence polygenic dyslipidemia also modify the effects of clinical
interventions designed to mitigate cardiovascular and metabolic
risk. This report is the first comprehensive effort to examine
validated lipid loci within the context of a large randomized
clinical trial. The findings of this study may facilitate the
implementation of complex trait genetics into the clinical setting.
Methods
Participants
The DPP was a multi-center randomized controlled trial that
examined the effects of metformin or intensive lifestyle modifica-
tion on the incidence of type 2 diabetes [33,34]. Briefly,
overweight persons with elevated but non-diabetic fasting and
post-challenge glucose levels were randomized to receive placebo,
metformin (850 mg twice daily) or a program of intensive lifestyle
modification. The lifestyle intervention was designed to achieve
,150 min/wk of physical activity and ,7% weight loss via focus
on daily fat gram goals. Fat gram goals were based on initial
weight and 25% of calories from fat using a calorie level estimate
to produce a weight loss of ,0.5–1 kg/wk. The principal endpoint
was the development of diabetes by confirmed semi-annual fasting
plasma glucose or annual oral glucose tolerance testing (OGTT).
Other phenotypes, such as changes in weight, waist circumference,
lipids, insulin and glucose, were also ascertained. Written,
informed consent was obtained from each participant, and each
of the 27 DPP centers obtained institutional review board approval
prior to initiation of the study protocol. A total of 2,993
participants in the placebo, lifestyle and metformin groups had
DNA available and provided consent for genetic analysis.
Individuals taking lipid lowering medications at baseline
(n=145) were excluded from all analyses.
Measurements
All participants fasted for $12 hrs the night before blood was
drawn from an antecubital vein. Standard blood lipid measure-
ments (triglyceride [TG], total cholesterol, HDL-C, calculated
LDL-C) were performed at the DPP central biochemistry
laboratory. TG and total cholesterol levels were measured using
enzymatic methods standardized to the Centers for Disease
Control and Prevention reference methods [35]. HDL fractions
for cholesterol analysis were obtained by the treatment of whole
plasma with dextran sulfate Mg
2+ [36]. LDL cholesterol was
calculated by the Friedewald equation [37]. In participants with
TGs.4.5 mmol/l, the lipoprotein fractions were separated using
preparative ultracentrifugation of plasma by b quantification [38].
Lipoprotein subclass particle concentrations and average VLDL,
LDL, and HDL particle diameters were measured by NMR
spectroscopy at LipoScience, Inc (Raleigh, NC) with modification
of existing methods [39].
Genotyping
Thirty-two SNPs previously associated with lipid concentrations
in GWAS meta-analyses [10] were selected. DNA was extracted
from peripheral blood leukocytes using standard methods.
Genotyping was performed by allele-specific primer extension of
multiplex amplified products and detection using matrix-assisted
laser desorption ionization time-of-flight mass spectrometry on a
Sequenom iPLEX platform [40]. The mean genotyping success
Table 3. Association of 32-SNP GRS with Baseline-Adjusted One-Year Lipid and Lipoprotein Traits (n=2,686).
Trait Placebo Metformin p ILS p
bGRS±SE bGRS±SE GRSxMet bGRS±SE GRS6ILS
n 895 884 – 907 –
Chol (mg/dl) +0.00160.001 20.000260.0012 0.42 +0.00460.001 0.09
LDL-C (mg/dl) +0.2060.22 20.0360.22 0.64 +0.8760.22 0.02
HDL-C (mg/dl) 20.00260.001 20.00160.001 0.78 20.00160.002 0.61
TG (mg/dl) +0.008±0.004 +0.00460.004 0.50 +0.00560.004 0.59
LDL size (nm) 20.000460.0009 20.0022±0.0009 0.17 20.002460.0009 0.22
Total VLDL particles (nmol/L) +0.000360.0058 +0.007760.0054 0.49 +0.0142±0.0059 0.12
Large VLDL particles (nmol/L) 20.0036620.0096 +0.010660.0106 0.46 +0.008560.0123 0.61
Total LDL particles (nmol/L) 20.002860.0027 +0.001360.0027 0.34 +0.003560.0030 0.10
Large HDL particles (mmol/L) 20.014±0.006 20.011±0.006 0.90 20.00960.006 0.89
Small HDL particles (mmol/L) 20.00160.003 +0.00160.003 0.56 +0.00160.006 0.45
Small LDL particles (nmol/L) 20.00260.008 +0.01360.008 0.24 +0.03060.012 0.01
HDL size (nm) 20.000460.0004 20.0009±0.0004 0.38 20.0011±0.0005 0.16
VLDL size (nm) 20.0000560.00165 +0.0001560.00169 0.97 20.0009660.00189 0.54
Total HDL particles (mmol/L) 20.000360.0015 20.002160.0016 0.36 20.001060.0017 0.76
All traits except LDL-C ln-transformed prior to analysis and presentation of beta coefficients and standard errors. Treatment-specific results in bold indicate p#0.05;
bold italics indicates p,0.01; underlined bold italics indicate p,0.001.
doi:10.1371/journal.pgen.1002895.t003
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PLOS Genetics | www.plosgenetics.org 7 August 2012 | Volume 8 | Issue 8 | e1002895rate was 96.7%. The minimum call rate was 94.0%. All SNPs were
in Hardy-Weinberg equilibrium within each self-reported ethnic
group.
Statistical Analysis
The SAS software v9.2 (SAS, Carey, NC) was used for
analyses. Baseline total cholesterol, HDL-C, TG and all
lipoprotein sub-fraction levels were natural log transformed for
non-normality, and LDL-C was evaluated directly. For replicat-
ing the previously reported associations of SNPs with baseline
traits and evaluating the association of the individual SNPs with
NMR lipoprotein particle sizes and numbers, measurements
were compared across genotypic groups by ANCOVA (general
model, 2 df F test for three possible genotypes), and evidence for
an additive effect of genotype was also evaluated using the
measured genotype approach, in which each genotype was
assigned a value of 0, 1 or 2 according to the number of minor
alleles. Analyses of baseline traits were adjusted for age, sex, self-
reported ethnicity (to minimize confounding due to potential
differences in both allele frequency and lipid traits across
ethnicities) and BMI. For the individual SNP analyses, the
Bonferroni-corrected P-value for significance was set at
P,0.0001 to account for multiple comparisons (32 SNPs614
traits=448 tests; 0.05/448=0.0001).
A genetic risk score (GRS) was calculated from the 32 SNPs
using the direction of association from the initial association
seen in the published meta-analysis [10]; for each SNP, an allele
w a sd e s i g n a t e da sar i s ka l l e l ei fit was associated with higher TG
or LDL-C and/or lower HDL-C. In order to be able to
incorporate all individuals in the analysis, including those
missing genotypes at one or more loci, a simple imputation
procedure within each self-reported ethnic group was imple-
mented (in order to account for allele frequency differences
across ethnicities) prior to score calculation. First, after coding
t h eg e n o t y p ea st h en u m b e ro fm i n o ra l l e l e s( 0 ,1o r2 ) ,a n
ethnicity-specific mean genotype was calculated and rounded to
the nearest whole number. Missing genotypes were replaced by
the appropriate rounded mean genotype [41]. We calculated a
GRS for each individual by adding up the number of risk alleles
for each of the 32 tested SNPs, where a risk allele was defined as
one associated with increased TG or LDL-C or decreased HDL.
The GRS was then included as a quantitative independent
variable in a multiple regression model for each baseline lipid/
lipoprotein trait to test for association, adjusted for age, sex, self-
reported ethnicity, and BMI. GRS quartiles were constructed
separately within each self-reported ethnicity prior to calculat-
ing quartile-specific arithmetic means or geometric means and
95% confidence intervals. To test for interaction of the risk
score with treatment, a multiple regression model was
constructed with the 1 year value as the outcome variable and
including GRS, lifestyle and metformin treatment and GRS6li-
festyle and GRS6metformin terms, along with adjustments for
the corresponding baseline trait, baseline age, sex and self-
reported ethnicity.
Sample Size and Power
A priori power calculations are an important study-planning tool,
providing relevant information on likely effect sizes and variances
is accessible. It is possible to obtain a broad understanding of the
power constraints of our study by extrapolating results from other
experimental settings (as described in detail in [42]), but specific a
priori power calculations could not be performed for the current
study because reliable effect estimates and variances for tests of
gene6treatment interactions for the index genotypes and pheno-
types were unavailable in the published literature at the time this
study was planned. Post-hoc power calculations were not per-
formed, as these are well known to cause bias when interpreting a
study’s results [43–46]. However, confidence intervals are included
in the figures, which give insight into the precision of the GRS
effect estimates and hence the power to detect those estimates in
the DPP cohort.
Supporting Information
Figure S1 a: Box plots for Small LDL particles measured at
baseline in the placebo arm of the Diabetes Prevention Program
stratified by level of the genetic risk score. b: Box plots for Small
LDL particles measured at baseline in the metformin arm of the
Diabetes Prevention Program stratified by level of the genetic risk
score. c: Box plots for Small LDL particles measured at baseline in
the lifestyle arm of the Diabetes Prevention Program stratified by
level of the genetic risk score. d: Box plots for Small LDL particles
measured at 1 yr follow-up in the placebo arm of the Diabetes
Prevention Program stratified by level of the genetic risk score. e:
Box plots for Small LDL particles measured at 1 yr follow-up in
the metformin arm of the Diabetes Prevention Program stratified
by level of the genetic risk score. f: Box plots for Small LDL
particles measured at 1 yr follow-up in the lifestyle arm of the
Diabetes Prevention Program stratified by level of the genetic risk
score.
(PPTX)
Table S1 Details of individual SNP replication results
(n#2,843). The table compares results for each of the SNP loci
in published meta-analysis and elsewhere with those reported here
in the DPP. Analyses and means adjusted for age, sex, ethnicity
and BMI.
(DOCX)
Table S2 Associations of individual SNPs with lipid or
lipoprotein traits significant at the Bonferroni-significant p-value
of ,0.0001 for additive model (see Table 1 for units). Shown are
geometric means for all traits except LDL-C, for which arithmetic
means are shown. All analyses and means adjusted for age, sex,
ethnicity and BMI.
(DOCX)
Table S3 Associations of individual SNPs with lipid or
lipoprotein traits measured at baseline in White participants from
the DPP (n=1,565). Analyses were performed to determine
whether population stratification owing to the mutliethnic nature
of the DPP is likely to confound the associations reported in the
main analyses. The comparability of the results in White DPP
participants with the main analyses indicates that confoudning by
population stratification is unlikely to underly the main results
reported here. Analyses and means adjusted for age, sex, and BMI.
(DOCX)
Figure 1. LDL-C levels. LDL-C levels at baseline and 1 year (A) and small LDL particle levels at baseline and 1 year (B) stratified by treatment group
and lipid GRS. Each column shows ethnicity-adjusted arithmetic (for LDL-C) or geometric (for small LDL particles) means (with upper 95% confidence),
stratified above and below (less than or equal to) the ethnic-specific median GRS value. Ethnic-specific median GRS values are 34 alleles for Caucasian,
African American and American Indian ethnicities and 35 for Hispanic and Asian/Pacific Islander ethnicities.
doi:10.1371/journal.pgen.1002895.g001
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